Research programme: ras oncogene pathway inhibitors - Millennium
Alternative Names: Ras oncogene research programme - MillenniumLatest Information Update: 23 Aug 2002
Price :
$50 *
At a glance
- Originator Millennium Pharmaceuticals
- Class
- Mechanism of Action Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
- 05 Nov 1999 ProScript has been acquired by LeukoSite
- 05 Nov 1999 The ras oncogene inhibitors research programme is available for licensing